ES2572267T3 - Composiciones de insulina de acción súper rápida - Google Patents

Composiciones de insulina de acción súper rápida

Info

Publication number
ES2572267T3
ES2572267T3 ES13193463T ES13193463T ES2572267T3 ES 2572267 T3 ES2572267 T3 ES 2572267T3 ES 13193463 T ES13193463 T ES 13193463T ES 13193463 T ES13193463 T ES 13193463T ES 2572267 T3 ES2572267 T3 ES 2572267T3
Authority
ES
Spain
Prior art keywords
acting insulin
fast
insulin
super
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13193463T
Other languages
English (en)
Inventor
Gregory Frost
Igor Bilinsky
Daniel Vaughn
Barry Sugarman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Halozyme Inc
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41037892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2572267(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Halozyme Inc filed Critical Halozyme Inc
Application granted granted Critical
Publication of ES2572267T3 publication Critical patent/ES2572267T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Una composición de insulina de acción súper rápida para uso para administración a un sujeto diabético para controlar los niveles de glucosa en sangre post-prandial en el sujeto, donde la composición de insulina de acción súper rápida comprende: una concentración terapéuticamente eficaz de un análogo de insulina de acción rápida para mantener los niveles de glucosa en sangre normales, donde un análogo de insulina de acción rápida es una insulina que comprende uno o más cambios de aminoácidos en insulina que reducen la autoasociación de la molécula de insulina, por lo que el análogo de insulina de acción rápida muestra una disociación más rápida de forma hexamérica a monomérica tras la administración subcutánea; y una concentración de una enzima degradante de hialuronano suficiente para convertir el análogo de insulina de acción rápida en una composición de insulina de acción súper rápida tras la administración, donde la composición de insulina de acción súper rápida tiene un inicio de acción que se asemeja estrechamente a la liberación de insulina postprandial endógena de un sujeto no diabético.
ES13193463T 2008-04-28 2009-04-28 Composiciones de insulina de acción súper rápida Active ES2572267T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12583508P 2008-04-28 2008-04-28
US12704408P 2008-05-09 2008-05-09

Publications (1)

Publication Number Publication Date
ES2572267T3 true ES2572267T3 (es) 2016-05-31

Family

ID=41037892

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09739183.3T Active ES2531630T3 (es) 2008-04-28 2009-04-28 Composiciones de insulina de acción súper rápida
ES13193463T Active ES2572267T3 (es) 2008-04-28 2009-04-28 Composiciones de insulina de acción súper rápida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09739183.3T Active ES2531630T3 (es) 2008-04-28 2009-04-28 Composiciones de insulina de acción súper rápida

Country Status (28)

Country Link
US (3) US8318154B2 (es)
EP (2) EP2300046B1 (es)
JP (3) JP2011523940A (es)
KR (2) KR101516464B1 (es)
CN (1) CN102083458B (es)
AR (1) AR072250A1 (es)
AU (1) AU2009241795B2 (es)
BR (1) BRPI0911782A2 (es)
CA (1) CA2722628C (es)
CL (1) CL2009001014A1 (es)
CY (1) CY1116311T1 (es)
DK (1) DK2300046T3 (es)
EA (1) EA029502B1 (es)
ES (2) ES2531630T3 (es)
HR (1) HRP20150313T1 (es)
IL (1) IL208554A0 (es)
MX (2) MX348276B (es)
NZ (1) NZ588748A (es)
PE (2) PE20141384A1 (es)
PL (1) PL2300046T3 (es)
PT (1) PT2300046E (es)
RS (1) RS53945B1 (es)
SG (1) SG10201404218VA (es)
SI (1) SI2300046T1 (es)
TW (1) TWI394580B (es)
UY (1) UY31789A1 (es)
WO (1) WO2009134380A2 (es)
ZA (1) ZA201007403B (es)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508948A1 (en) 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
CA2702116C (en) 2007-10-10 2021-01-05 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2720304C (en) * 2008-04-04 2018-05-15 Hygieia, Inc. Apparatus for optimizing a patient's insulin dosage regimen
KR20130116386A (ko) * 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
EA022752B1 (ru) * 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
US20110250273A1 (en) * 2008-12-11 2011-10-13 Melford Scientific, LLC Compositions of proton pump inhibitors, kits and methods of their use to treat diabetes
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CN102596175A (zh) * 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) * 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
US9144586B2 (en) 2010-04-07 2015-09-29 Incube Labs, Llc Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells
CA2805031A1 (en) * 2010-07-07 2012-01-12 Biodel, Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
WO2012012300A2 (en) 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CA2839512C (en) * 2011-06-17 2018-01-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
NZ618331A (en) * 2011-06-17 2016-04-29 Halozyme Inc Stable formulations of a hyaluronan-degrading enzyme
EP2543725A1 (en) 2011-07-08 2013-01-09 Biomay Ag Polysaccharide lyases
DK2741765T3 (en) * 2011-08-10 2016-06-13 Adocia Injectable solution of at least one type of basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013040501A1 (en) * 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
WO2014096985A2 (en) * 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
US9486578B2 (en) * 2012-12-07 2016-11-08 Animas Corporation Method and system for tuning a closed-loop controller for an artificial pancreas
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
UA117480C2 (uk) 2013-04-03 2018-08-10 Санофі Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
US20160067190A1 (en) * 2013-04-30 2016-03-10 The Children's Medical Center Corporation Injectable nano-network gels for diabetes treatment
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
US10569015B2 (en) 2013-12-02 2020-02-25 Bigfoot Biomedical, Inc. Infusion pump system and method
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016015851A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
TN2017000178A1 (en) * 2014-11-21 2018-10-19 Merck Sharp & Dohme Insulin receptor partial agonists
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
CN111905188B (zh) 2015-02-18 2022-07-22 英赛罗公司 流体输送和输注装置及其使用方法
BR112017018060A2 (pt) 2015-02-25 2018-04-10 Dance Biopharm Inc formulação de insulina, dose de unidade, e, método de tratar um indivíduo com diabetes melito.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US9981021B1 (en) * 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
US9878097B2 (en) 2015-04-29 2018-01-30 Bigfoot Biomedical, Inc. Operating an infusion pump system
DE102015107307B3 (de) * 2015-05-11 2016-09-08 Labor L + S Aktiengesellschaft Optisches Verfahren zur Gehaltsbestimmung von Hyaluronsäure
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
CN108472440B (zh) 2016-01-05 2021-11-09 比格福特生物医药公司 操作多模式药物输送系统
US10449294B1 (en) 2016-01-05 2019-10-22 Bigfoot Biomedical, Inc. Operating an infusion pump system
WO2017123525A1 (en) 2016-01-13 2017-07-20 Bigfoot Biomedical, Inc. User interface for diabetes management system
HK1256995A1 (zh) 2016-01-14 2019-10-11 Bigfoot Biomedical, Inc. 药物输送设备、系统和方法中的阻塞解决方案
US10806859B2 (en) 2016-01-14 2020-10-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US12383166B2 (en) 2016-05-23 2025-08-12 Insulet Corporation Insulin delivery system and methods with risk-based set points
WO2017210242A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Insulin-nuclear hormone conjugates
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
US10765807B2 (en) 2016-09-23 2020-09-08 Insulet Corporation Fluid delivery device with sensor
JP2019529506A (ja) 2016-09-29 2019-10-17 アレコル リミテッド 新規の製剤
US11096624B2 (en) 2016-12-12 2021-08-24 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and systems
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US11033682B2 (en) 2017-01-13 2021-06-15 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881792B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP3568860B1 (en) 2017-01-13 2025-12-10 Insulet Corporation Insulin delivery methods, systems and devices
JP6874155B2 (ja) 2017-05-05 2021-05-19 イーライ リリー アンド カンパニー 生理的グルコースの閉ループ制御
CN110662551B (zh) 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
EP3639168B1 (en) 2017-06-15 2022-05-11 Novo Nordisk A/S Insulin titration algorithm based on patient profile
CN117912631A (zh) 2017-06-15 2024-04-19 诺和诺德股份有限公司 具有适应性靶葡萄糖水平的基础滴定
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
WO2019125932A1 (en) 2017-12-21 2019-06-27 Eli Lilly And Company Closed loop control of physiological glucose
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
US12357562B2 (en) 2018-04-04 2025-07-15 Arecor Limited Injection pen system for the delivery of an insulin compound
US11147919B2 (en) 2018-04-23 2021-10-19 Medtronic Minimed, Inc. Methodology to recommend and implement adjustments to a fluid infusion device of a medication delivery system
US11158413B2 (en) * 2018-04-23 2021-10-26 Medtronic Minimed, Inc. Personalized closed loop medication delivery system that utilizes a digital twin of the patient
US11565043B2 (en) 2018-05-04 2023-01-31 Insulet Corporation Safety constraints for a control algorithm based drug delivery system
US12562251B1 (en) 2018-05-09 2026-02-24 Bigfoot Biomedical, Inc. Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices
CN112313754A (zh) 2018-06-22 2021-02-02 伊莱利利公司 胰岛素和普兰林肽输送系统、方法和设备
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
AU2019347755B2 (en) 2018-09-28 2023-02-02 Insulet Corporation Activity mode for artificial pancreas system
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11986629B2 (en) 2019-06-11 2024-05-21 Medtronic Minimed, Inc. Personalized closed loop optimization systems and methods
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
JPWO2021065768A1 (es) * 2019-09-30 2021-04-08
EP4049032A1 (en) 2019-10-25 2022-08-31 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
EP4069082B1 (en) 2019-12-06 2024-06-05 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
JP7512395B2 (ja) 2020-01-06 2024-07-08 インスレット コーポレイション 持続する残差に基づく食事および／または運動行為の予測
EP4100958A1 (en) 2020-02-03 2022-12-14 Insulet Corporation Use of fuzzy logic in predicting user behavior affecting blood glucose concentration
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
US12495994B2 (en) 2020-02-20 2025-12-16 Insulet Corporation Meal bolus subcategories in model based insulin therapy
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US12121700B2 (en) 2020-07-22 2024-10-22 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US20220062545A1 (en) * 2020-08-31 2022-03-03 Insulet Corporation Techniques for determining insulin formulations in an automated insulin delivery system
US12569619B2 (en) 2020-09-21 2026-03-10 Insulet Corporation Techniques for determining automated insulin delivery dosages
US12178852B2 (en) 2020-09-30 2024-12-31 Willow Laboratories, Inc. Insulin formulations and uses in infusion devices
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
EP4696344A3 (en) 2020-09-30 2026-04-15 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor
WO2022098906A1 (en) * 2020-11-04 2022-05-12 The Trustees Of The University Of Pennsylvania Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs
US11160925B1 (en) 2021-01-29 2021-11-02 Insulet Corporation Automatic drug delivery system for delivery of a GLP-1 therapeutic
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
EP4305636A1 (en) 2021-03-10 2024-01-17 Insulet Corporation A medicament delivery device with an adjustable and piecewise analyte level cost component to address persistent positive analyte level excursions
US12592306B2 (en) 2021-04-28 2026-03-31 Insulet Corporation Devices and methods for initialization of drug delivery devices using measured analyte sensor information
US12496398B2 (en) 2021-05-28 2025-12-16 Insulet Corporation Threshold based automatic glucose control response
EP4101482A1 (en) 2021-06-07 2022-12-14 Insulet Corporation Exercise safety prediction based on physiological conditions
US12514980B2 (en) 2021-06-30 2026-01-06 Insulet Corporation Adjustment of medicament delivery by a medicament delivery device based on menstrual cycle phase
US20230025595A1 (en) * 2021-07-13 2023-01-26 America Great Health, a California Corporation Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration
US12521486B2 (en) 2021-07-16 2026-01-13 Insulet Corporation Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems
WO2023049900A1 (en) 2021-09-27 2023-03-30 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
KR20240167718A (ko) * 2022-03-01 2024-11-27 스카우트 바이오, 인코포레이티드 인슐린 융합 단백질
AU2023228669A1 (en) * 2022-03-01 2024-09-19 Scout Bio, Inc. Viral vector genome encoding an insulin fusion protein
EP4243030A1 (en) 2022-03-09 2023-09-13 Insulet Corporation Adjusting medicament delivery parameters in an open loop medicament delivery mode
WO2023178158A1 (en) * 2022-03-18 2023-09-21 Mannkind Corporation Optimization of dosing and prescribing of medication
CN114634920B (zh) * 2022-03-24 2024-02-27 江南大学 一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法
CN114632092B (zh) * 2022-05-17 2022-08-23 北京第一生物化学药业有限公司 睾丸片在制备具有降糖活性的药物中的应用
CN115227724B (zh) * 2022-09-21 2023-03-24 首都医科大学附属北京友谊医院 缓慢葡萄球菌在制备组合物中的应用
AR131148A1 (es) * 2022-11-26 2025-02-19 Obshchestvo S Ogranichennoy Otvetstvennostyu «Geropharm» Composiciones de insulina de acción rápida (variantes de las mismas)
EP4637716A1 (en) 2022-12-22 2025-10-29 Halozyme, Inc. Hyaluronidase enzyme formulations for high volume administration
EP4646726A1 (en) 2023-01-06 2025-11-12 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2026085414A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085417A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085415A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
WO2026085419A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US467840A (en) 1892-01-26 Water-wheel
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4573994A (en) 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
JPS5951355A (ja) 1982-09-17 1984-03-24 Fujirebio Inc 抗ウイルス抗体検出用試薬
US4562751A (en) 1984-01-06 1986-01-07 Nason Clyde K Solenoid drive apparatus for an external infusion pump
US4685903A (en) 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
EP0162007A1 (de) * 1984-04-18 1985-11-21 Geriaco AG Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
WO1989006989A1 (en) 1988-01-29 1989-08-10 The Regents Of The University Of California Iontophoretic non-invasive sampling or delivery device
US4973318A (en) 1988-02-10 1990-11-27 D.C.P. Af 1988 A/S Disposable syringe
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
DK134691D0 (da) 1991-07-12 1991-07-12 Novo Nordisk As Apparat
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5433197A (en) 1992-09-04 1995-07-18 Stark; Edward W. Non-invasive glucose measurement method and apparatus
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5497772A (en) 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5657947A (en) * 1994-08-24 1997-08-19 Loral Corp. Precision guidance system for aircraft launched bombs
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ATE278801T1 (de) 1995-11-22 2004-10-15 Medtronic Minimed Inc Detektion von biologischen molekülen unter verwendung von chemischer amplifikation und optischem sensor
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US5747806A (en) 1996-02-02 1998-05-05 Instrumentation Metrics, Inc Method and apparatus for multi-spectral analysis in noninvasive nir spectroscopy
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
IL127557A0 (en) 1996-07-05 1999-10-28 Novo Nordisk As Flexible piston rod
US5665069A (en) 1996-07-19 1997-09-09 Cumer; Patricia Lynn Pressure-directed peribulbar anesthesia delivery device
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5947934A (en) 1996-09-13 1999-09-07 Novo Nordisk A/S Dose display for an injection syringe
US6110149A (en) 1996-09-13 2000-08-29 Novo Nordisk A/S Syringe
US6379339B1 (en) 1996-09-13 2002-04-30 Nova Nordisk A/S Syringe
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6123938A (en) 1996-10-17 2000-09-26 The Regents Of The University Of California Human urinary hyaluronidase
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US6074372A (en) 1997-06-09 2000-06-13 Novo Nordisk A/S Dose setting mechanism and an injection syringe having such a dose setting mechanism
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
US6093167A (en) 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1021248B1 (en) 1997-10-09 2005-12-28 Kadant Black Clawson Inc. Paper pulp refiner control system and method
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
CN1314992A (zh) 1998-07-03 2001-09-26 奈勒斯菲尔德控制有限公司 流体测量的方法和装置
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6669663B1 (en) * 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
TW453884B (en) 1999-09-16 2001-09-11 Novo Nordisk As Dose setting limiter
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
JP2003534834A (ja) 2000-01-28 2003-11-25 ノボ ノルディスク アクティーゼルスカブ 投与量設定リミッター
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6740042B1 (en) 2001-09-05 2004-05-25 Biomedix, Inc. Bilateral simultaneous doppler measurement of segmented sphygmomanometry
US6740072B2 (en) 2001-09-07 2004-05-25 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US7368108B2 (en) 2001-11-28 2008-05-06 Neose Technologies, Inc. Glycopeptide remodeling using amidases
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
AU2002360370A1 (en) 2001-12-03 2003-06-17 Eli Lilly And Company Medication delivery device having communication capability with glucose monitor
US6744350B2 (en) 2002-02-28 2004-06-01 Smiths Medical Md, Inc. Insulin pump having missed meal bolus alarm
US6852104B2 (en) 2002-02-28 2005-02-08 Smiths Medical Md, Inc. Programmable insulin pump
US7192468B2 (en) 2002-04-15 2007-03-20 Fluor Technologies Corporation Configurations and method for improved gas removal
EP1539033A1 (en) 2002-08-07 2005-06-15 Memry Corporation Implantable artificial pancreas
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
CA2508948A1 (en) 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ542873A (en) * 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US7025713B2 (en) 2003-10-13 2006-04-11 Icon Ip, Inc. Weight lifting system with internal cam mechanism
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US6999854B2 (en) 2004-05-28 2006-02-14 International Business Machines Corporation Medical infusion pump capable of learning bolus time patterns and providing bolus alerts
US7572613B2 (en) 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP3912395B2 (ja) * 2004-07-12 2007-05-09 セイコーエプソン株式会社 半導体集積回路、検査装置および半導体集積回路の検査方法
US20070244467A1 (en) 2005-09-28 2007-10-18 Biodel, Inc., State Of Incorporation Delaware Self-Filling Two Chamber Injectable Device
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) * 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
US20070191757A1 (en) 2006-02-16 2007-08-16 Biodel Inc. Method and Device for Sublingual Drug Delivery Using Iontophoresis
WO2007098479A2 (en) * 2006-02-21 2007-08-30 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
EP2012817A2 (en) 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US20070243567A1 (en) 2006-04-13 2007-10-18 Syhhong Chang Beta cell mimicking control algorithm for artificial pancreas
WO2008016729A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
RU2471867C2 (ru) 2007-06-19 2013-01-10 Тамара П. Уваркина Гиалуронидаза и способ ее применения
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
WO2012012300A2 (en) 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CA2839512C (en) 2011-06-17 2018-01-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法

Also Published As

Publication number Publication date
US20140135682A1 (en) 2014-05-15
PL2300046T3 (pl) 2015-06-30
SG10201404218VA (en) 2014-10-30
JP2016034959A (ja) 2016-03-17
MX2010011849A (es) 2010-12-15
RS53945B1 (sr) 2015-08-31
HRP20150313T1 (hr) 2015-06-05
AU2009241795B2 (en) 2013-05-09
WO2009134380A8 (en) 2010-03-18
CA2722628A1 (en) 2009-11-05
ES2531630T3 (es) 2015-03-18
EP2705850B1 (en) 2016-04-27
CL2009001014A1 (es) 2009-06-19
SI2300046T1 (sl) 2015-04-30
BRPI0911782A2 (pt) 2018-03-13
US8318154B2 (en) 2012-11-27
PE20141384A1 (es) 2014-10-10
KR101516534B1 (ko) 2015-05-04
UY31789A1 (es) 2009-08-31
EP2300046B1 (en) 2014-12-24
HK1195728A1 (en) 2014-11-21
PE20091975A1 (es) 2010-01-09
JP2011523940A (ja) 2011-08-25
EA201001698A1 (ru) 2011-08-30
EP2705850A2 (en) 2014-03-12
CN102083458A (zh) 2011-06-01
HK1150967A1 (en) 2012-01-20
TWI394580B (zh) 2013-05-01
US8568713B2 (en) 2013-10-29
PT2300046E (pt) 2015-04-08
EP2300046A2 (en) 2011-03-30
KR101516464B1 (ko) 2015-06-19
AR072250A1 (es) 2010-08-18
MX348276B (es) 2017-06-02
US20120251517A1 (en) 2012-10-04
CN102083458B (zh) 2016-01-20
CA2722628C (en) 2016-08-16
KR20110021818A (ko) 2011-03-04
TW201000121A (en) 2010-01-01
DK2300046T3 (en) 2015-03-23
WO2009134380A3 (en) 2009-12-30
NZ588748A (en) 2012-09-28
US20090304665A1 (en) 2009-12-10
ZA201007403B (en) 2019-06-26
EP2705850A3 (en) 2014-04-02
CY1116311T1 (el) 2017-02-08
JP5809330B2 (ja) 2015-11-10
IL208554A0 (en) 2010-12-30
WO2009134380A2 (en) 2009-11-05
EA029502B1 (ru) 2018-04-30
JP2014208686A (ja) 2014-11-06
AU2009241795A1 (en) 2009-11-05
KR20140093759A (ko) 2014-07-28
US9034323B2 (en) 2015-05-19

Similar Documents

Publication Publication Date Title
ES2572267T3 (es) Composiciones de insulina de acción súper rápida
PH12019500517A1 (en) Long-acting formulations of insulins
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
EA201100865A1 (ru) Композиции со сниженным образованием димеров
ECSP13012661A (es) Composición farmacéutica, métodos de tratamiento y usos de la misma.
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CL2011001635A1 (es) Uso de un inhibidor de dpp-4 oral, el cual es 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)xantina, en una cantidad de 1-10 mg, y metformina para preparar una composicion farmaceutica util para mejorar el control glicemico en pacientes con diabetes tipo 2.
CL2012001232A1 (es) Composicion farmaceutica liquida que comprende un agonista de glp-1: despro36 exendina-4-(1-39)-lys6-nh2, insulina humana gly(a21)-arg(b31)-arg(b32), o sales de ellos, l-metionina y opcionalmente un excipiente; combinacion; kit; metodo de preparacion; uso para tratar la diabetes.
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AR077454A1 (es) Preparaciones insulinicas que comprenden metionina
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
PE20161408A1 (es) Composiciones de insulina de rapida accion
BR112014010275A2 (pt) formulações para tratamento de diabetes
BRPI0905369B8 (pt) composição farmacêutica, uso da composição farmacêutica e kit compartimentado
BRPI0818903B8 (pt) formulação líquida contendo anticorpo de concentração elevada e métodos para inibir a desamidação e dimerização de moléculas de um anticorpo em uma formulação líquida contendo o anticorpo
CL2012002031A1 (es) Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
MX2009008166A (es) Metodo para disminuir la inflamacion y estres en un mamifero usando antimetabolitos de glucosa, aguacate o extractos de aguacate.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
MX2012003565A (es) Agentes de despeje de peptido.
BR112015014334A2 (pt) método de tratamento usando o lactobacillus fermentum me-3
PE20191836A1 (es) Compuesto de insulina acilada